Peer-influenced content. Sources you trust. No registration required. This is HCN.

The Journal of Clinical Investigation (JCI)Pre-clinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast

PDE4 is linked to alcohol and nicotine addiction, so the researchers prioritized apremilast, a newer PDE4 inhibitor for psoriasis, as ideal for repurposing and tested it in multiple animal strains and models, as well as a human Phase IIa study. In mouse models of genetic risk for drinking to intoxication, they discovered that apremilast reduced binge-like alcohol intake and behavioral measures of alcohol motivation.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form